Quantcast

Latest hypoglycemia Stories

2011-06-24 16:00:00

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announce Phase III study results for linagliptin, demonstrating improved glycemic control in adults with type 2 diabetes (T2D) whose blood sugar is not adequately controlled. In the open-label arm (n=66) of a 24-week study in adult patients with T2D with a mean baseline hemoglobin A1c (HbA1c or A1C) of 11.8 percent receiving linagliptin 2.5 mg twice daily (bid) plus metformin 1000 mg...

2011-06-24 16:00:00

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced data from a new analysis characterizing the effects of SYMLIN® (pramlintide acetate) injection in patients with type 1 diabetes who used insulin pumps during two previously completed clinical studies. The data, which will be presented during a poster presentation at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego, demonstrated that...

2011-06-24 16:00:00

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from long-term extensions of the DURATION-1 and 3 studies evaluating BYDUREON(TM) (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes. The studies will be presented at the 71st Scientific Sessions of the American Diabetes Association. Data from the DURATION-1...

2011-06-20 11:51:00

Guidance outlines recommendations for clinical trials and pathway to market approval SILVER SPRING, Md., June 20, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today issued draft guidance that will help advance the development and approval of an artificial pancreas system to treat type 1 diabetes in the United States. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Type 1 diabetes is a chronic condition in which the pancreas produces little or no...

2011-06-08 07:00:00

INDIANAPOLIS, June 8, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental new drug application (sNDA) with the following updates to the Humalog label: continuous insulin infusion pump therapy in children 4 years of age and over with type 1 diabetes extension of the time-in-use in the external pump reservoir to a maximum of seven days; and extension of the time-in-use of the infusion...

2011-06-06 09:43:00

COPENHAGEN, Denmark, June 6, 2011 /PRNewswire/ -- Nearly one in five people with diabetes are regularly unable to attend a full day at work due to disruption caused by episodes of dangerously low blood sugar, known as a hypoglycaemic event.( )A new survey, focusing on productivity loss following hypoglycaemic events, was published today in the journal Value in Health. The survey was conducted with 1,404 people with type 1 and type 2 diabetes who had reported a hypoglycaemic event in the...

2011-06-01 06:30:00

CHENGDU, China, June 1, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced TPI has received the production license for its anti-diabetic drug Gliclazide Tablets (80 mg formulation) from China's State Food and Drug Administration (SFDA). The national pharmaceutical certificate...

2011-05-13 06:00:00

CHENGDU, China, May 13, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced that TPI has received the China's SFDA's approval for its anti-diabetic drug Gliclazide Tablets (80 mg formulation). Gliclazide is an oral anti-diabetic drug that is used for the control of...

2011-04-21 08:00:00

PRINCETON, N.J., April 21, 2011 /PRNewswire/ -- Today, Novo Nordisk announced the launch of the NovoTwist® needle in the United States. The NovoTwist® needle, which is now available for use with several Novo Nordisk pre-filled delivery devices, including Levemir® (insulin detemir [rDNA origin] injection) FlexPen®, NovoLog® (insulin aspart [rDNA origin] injection) FlexPen®,...

2011-04-18 21:20:02

A new study of older diabetes patients has found that well-controlled blood sugar levels were associated with a lower risk of major complications such as heart attacks, amputation and kidney disease, but the very lowest blood sugar levels were associated with a small but significant increased risk of death. The study published in the June 2011 issue of the journal Diabetes Care, followed more than 70,000 type 2 diabetes patients from Kaiser Permanente who were over 60 years of age for four...


Latest hypoglycemia Reference Libraries

0_0d961f30bdfa64859d9b869b063ddcd2
2010-12-03 18:12:26

Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...

More Articles (1 articles) »
Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related